Tag Archives: Clinical trial

May 22 2013 – Promedior Presents Encouraging Results from Clinical Study of PRM-151 in Patients with Idiopathic Pulmonary Fibrosis

LEXINGTON, Mass., May 22, 2013 —Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, unveiled data from a clinical study of PRM-151 in an oral presentation at the 2013 American Thoracic Society (ATS) … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , | Leave a comment

May 21 2013 – Genetic variation among patients with pulmonary fibrosis associated with improved survival

Variation in the gene MUC5B among patients with idiopathic pulmonary fibrosis was associated with improved survival, according to a study published online by JAMA. The study is being released early online to coincide with its presentation at the American Thoracic … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , | Leave a comment

May 21 2013 – Race Horses May Hold Key to Cure for Deadly Lung Disease Killing Humans, Horses, Other Domestic Animals

LOUISVILLE, Ky., May 20, 2013 /PRNewswire-USNewswire/ — Researchers from human and veterinary medicine want to know more about the lung disease that is killing horses, including thoroughbred horses and other domestic animals, just as it’s claiming an increasing number of … Continue reading

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , | Leave a comment

May 16 2013 – Promedior to Present Clinical Data on Lead Drug Candidate, PRM-151, in Patients with IPF at the ATS 2013 Annual Meeting

LEXINGTON, Mass.–(BUSINESS WIRE)–May 16, 2013– Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, today announced that data from a clinical study of PRM-151 in patients with idiopathic pulmonary fibrosis (IPF) will be … Continue reading

Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , | Leave a comment

May 8 2013 US/EU – Idiopathic pulmonary fibrosis drug sales “to rise 86.6%/year to 2017″

The idiopathic pulmonary fibrosis (IPF) therapy market across the US and European Union (EU) will be worth more than $1.1 billion by 2017, and pharma companies could stand to benefit handsomely if they can add to the limited knowledge of … Continue reading

Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , | Leave a comment

May 6 2013 – Ambrisentan Fails in Lung Fibrosis

The pulmonary hypertension drug ambrisentan (Letairis) was supposed to tackle one of the root causes of idiopathic pulmonary fibrosis but actually worsened that disease, the ARTEMIS-IPF clinical trial showed. In relatively mild IPF patients, ambrisentan appeared to accelerate disease progression … Continue reading

Posted in Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , | Leave a comment